A global coalition announced it will fast-track three vaccines targeting the Ebola virus currently spreading in the Congo, committing $62 million to the effort. No licensed vaccines currently exist for this particular strain, according to STAT News.
The funding aims to compress typical development timelines, though specific regulatory and trial milestones remain undisclosed. The push comes as health authorities race to contain the outbreak, which has raised alarms due to the lack of available protection.
None of the three candidates have yet been named, and details on clinical trial locations or participant numbers were not provided. The $62 million pledge comes from CEPI, a global epidemic-response group, according to the source.
Without existing stockpiles or approved treatments, containment relies heavily on public health measures and rapid vaccine development. The success of this accelerated approach could set precedents for future outbreak responses.
Experts caution that even with fast-tracked programs, a licensed vaccine may still be months or years away from widespread use.